Amneal Pharmaceuticals announced that it has launched CREXONT or carbidopa and levodopa, extended-release capsules for the treatment of Parkinson’s disease. CREXONT is a novel, oral formulation of carbidopa/levodopa or CD/LD, that combines both immediate-release granules and extended-release pellets. CREXONT is now broadly available at U.S. pharmacies. “We are pleased to launch CREXONT and make it broadly available to healthcare providers and patients. The product’s innovative formulation provides a longer duration of “Good On” time with less frequent dosing compared to immediate release CD/LD. As a leader in the Parkinson’s space, Amneal has a long history of working closely with movement disorder specialists and neurologists. We are excited to build on this foundation with the rollout of a comprehensive education program and extensive services to help healthcare providers and patients access this innovative therapy,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals upgraded to Neutral from Underweight at JPMorgan
- Amneal Pharmaceuticals announces FDA approval of BORUZU
- Amneal Pharmaceuticals receives FDA approval for Propofol Injectable Emulsion
- Amneal Pharmaceuticals price target raised to $10 from $8 at Barclays
- Generic Mucinex at risk of containing potent carcinogen, Bloomberg says